Every 8-K that Autonomix Medical, Inc. (AMIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AMIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMIX filings page.
Autonomix Medical, Inc. (AMIX) entered into a warrant inducement transaction with an investor holding previously issued Series D-1 and D-2 warrants. The investor agreed to immediately exercise warrants to purchase 857,462 shares of common stock at an exercise price of $5.75 per share, generating expected gross proceeds of about $4.9 million before fees and expenses.
In consideration for this cash exercise, Autonomix will issue unregistered Series E-1 and Series E-2 warrants, each to purchase up to 535,913 shares of common stock, with a $6.25 exercise price and a 5-year term. The new warrants include a 4.99% or 9.99% Beneficial Ownership Limitation, are exercisable immediately, and may be exercised on a cashless basis under specified registration shortfalls. In a fundamental transaction, holders receive alternate consideration, and the Series E-2 warrants include a Black Scholes-based redemption right.
The new warrants are being issued in a private placement under Section 4(a)(2) of the Securities Act, and Autonomix agreed to file a resale registration statement for the underlying shares within set timeframes. Maxim Group LLC acted as financial advisor and warrant inducement agent, to receive a 7.0% cash fee on proceeds plus up to $15,000 in expense reimbursement.
Autonomix Medical, Inc. reported that as of July 28, 2026, its cash balance was approximately $5.1 million and it had 971,043 shares of common stock outstanding.
The outstanding share count includes common shares issued in connection with a warrant inducement dated July 13, 2026, providing an updated snapshot of the company’s cash position and capital structure.
Autonomix Medical, Inc. entered into a warrant inducement arrangement with an existing investor covering Series C/November 2025 warrants to purchase 428,731 shares of common stock. The company reduced the exercise price on these registered warrants to $6.00 per share, and the investor agreed to exercise them for anticipated gross proceeds of about $2.6 million, before fees and expenses.
In return, Autonomix will issue the investor two new unregistered warrant series, D-1 and D-2, each exercisable for up to 428,731 shares at $5.75 per share, with a 5.5-year term and beneficial ownership caps of 4.99% or 9.99%. The company committed to file, within 15 days, a resale registration statement for the shares underlying these new warrants and to seek effectiveness within 45 to 75 days, while paying Maxim Group LLC a 7.0% cash fee on warrant-exercise proceeds plus up to $15,000 of expenses.
Autonomix Medical, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for listing on the Nasdaq Capital Market. The company had previously received a Nasdaq deficiency notice on January 14, 2026 after its common stock closed below $1.00 per share for 30 consecutive business days. Nasdaq informed Autonomix on July 9, 2026 that the closing bid price was at or above $1.00 per share for 10 consecutive business days from June 24, 2026 through July 8, 2026, restoring compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq has indicated the matter is closed.
Autonomix Medical, Inc. is implementing a 1-for-21 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on June 24, 2026. The shares will continue trading on the Nasdaq Capital Market under the symbol AMIX with a new CUSIP 05330T304.
Every 21 issued and outstanding common shares will be combined into one share, with the par value remaining $0.001. The number of common shares outstanding will be reduced from 11,409,344 to approximately 542,000, while authorized common shares will remain at 500 million.
Proportionate adjustments will be made to outstanding stock options, warrants and equity plan reserves. No fractional shares will be issued; instead, holders entitled to a fraction will receive cash based on the average closing price over the five trading days preceding the split.
The company also provided illustrative financial data, showing that for the year ended March 31, 2026, net loss was $16.7 million and net loss per common share – basic and diluted – adjusts from $2.32 pre-split to $48.80 post-split after applying the reverse split ratio.
Autonomix Medical, Inc. received a notice from Nasdaq that its common stock has failed to meet the minimum $1.00 per share bid price requirement for the last 30 consecutive business days, triggering a deficiency under Nasdaq’s continued listing rules.
The company has an initial 180-day grace period until July 13, 2026 to regain compliance by having its closing bid price at or above $1.00 for at least 10 consecutive business days. If it still falls short, Autonomix may qualify for a second 180-day period if it meets other Nasdaq Capital Market listing standards.
If compliance is not restored and no additional period is granted, Autonomix’s common stock may be delisted from Nasdaq, although the company could appeal. Management is monitoring the share price and may consider options such as a reverse stock split, but there is no assurance it will regain compliance.
Autonomix Medical, Inc. furnished an update highlighting new subgroup clinical data from its proof-of-concept study in pancreatic cancer-related pain. The analysis, presented at the 2026 ASCO Gastrointestinal Cancers Symposium, is described as demonstrating rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages, expanding on previously reported results from the ongoing evaluation.
The company also posted an updated corporate presentation on its website, which is included as an exhibit. Both the press release and the investor presentation are furnished under a Regulation FD disclosure and are not deemed filed under federal securities laws unless later specifically incorporated by reference.
Autonomix Medical, Inc. entered into a Securities Purchase Agreement with an institutional investor for a private placement of pre-funded and Series C common stock warrants, raising gross proceeds of approximately $5.0 million before fees. The investor purchased pre-funded warrants for 4,501,666 shares at a combined price of $1.1097 per pre-funded warrant plus accompanying Series C common warrants, with the pre-funded warrants exercisable at $0.001 per share and the common warrants exercisable at $0.8607 per share for up to 9,003,332 shares. The company plans to use the net proceeds for working capital and general corporate purposes, has agreed to register the resale of the warrant shares, and is subject to agreed limits on additional equity and variable-rate transactions for a period tied to the effectiveness of that registration statement.
Autonomix Medical (AMIX) reported stockholder voting results from its Annual Meeting. A total of 2,871,639 shares voted, representing approximately 48% of the 5,941,992 shares outstanding as of September 8, 2025, establishing a quorum. All five director nominees were elected. Stockholders ratified Forvis Mazars, LLP as independent auditor with 2,609,156 votes for, 91,309 against, and 171,174 abstentions.
Key approvals included capital flexibility items. Stockholders authorized the Board to implement a reverse stock split at a ratio between 1-for-2 and 1-for-25 prior to the one-year anniversary of the meeting (1,927,998 for; 370,030 against; 573,611 abstain). They approved the amended and restated 2023 Equity Incentive Plan (1,113,523 for; 127,874 against; 38,301 abstain) and, for Nasdaq Listing Rule 5635(d) purposes, authorized issuing more than 20% of outstanding common stock under the Lincoln Park Capital Fund, LLC purchase agreement (1,184,885 for; 75,982 against; 18,831 abstain).
Autonomix Medical, Inc. amended its at-the-market equity program by increasing the aggregate sales price available under its At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. On August 25, 2025 the company increased the original capacity of $2.1 million by an additional $1.4 million, and any sales will be made under the company’s effective Form S-3 registration statement (File No. 333-285464) and related prospectus supplement filed August 25, 2025. The filing references the February 28, 2025 sales agreement and legal opinions from ArentFox Schiff LLP.
Autonomix Medical, Inc. (AMIX) entered into a purchase agreement with Lincoln Park Capital Fund, LLC on August 25, 2025, under which Lincoln Park committed to purchase up to $15.0 million of the company’s common stock over a period of up to 24 months, subject to a Commencement Date that requires an effective registration statement and satisfaction of other conditions. The company issued 261,932 commitment shares to Lincoln Park as consideration. Daily purchases (Regular Purchases) are limited by share-count and a per-transaction dollar cap of $500,000, with purchase price formulas tied to recent trading prices and additional mechanics for accelerated purchases. Limits include a Nasdaq 19.99% exchange cap (unless shareholder approval is obtained or average price conditions are met) and a 4.99% beneficial ownership cap for Lincoln Park. Proceeds are expected to be used for working capital and general corporate purposes.